14 19

Cited 0 times in

안드로겐탈모증의 약물치료

DC FieldValueLanguage
dc.contributor.author김도영-
dc.date.accessioned2020-09-28T11:39:58Z-
dc.date.available2020-09-28T11:39:58Z-
dc.date.issued2020-05-
dc.identifier.issn1975-8456-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179238-
dc.description.abstractAndrogenetic alopecia (AGA) is the most common type of hair loss and affects both men and women. Male pattern hair loss shows characteristic frontal recession and vertex baldness, whereas female pattern hair loss produces diffuse alopecia over the mid-frontal scalp. AGA is mediated by increased androgen susceptibility in affected scalp hairs. 5α-Reductase converts testosterone into dihydrotestosterone, a potent androgen, in the scalp. Both androgen receptors and 5α-reductase have higher expression levels in the balding scalp than in non-affected regions. Increased androgen susceptibility induces hair follicle miniaturization, which leads to the progressive loss of thicker terminal hairs in the balding scalp. Currently, topical minoxidil and oral 5α-reductase inhibitors, such as finasteride and dutasteride, are approved options for the pharmacological treatment of AGA. Topical minoxidil remains the mainstay of therapy for mild to moderate AGA in both men and women. The daily intake of 1-mg finasteride or 0.5-mg dutasteride shows better efficacy than topical minoxidil in regard to hair regrowth in male AGA. Anti-androgens can be used in female AGA wit clinical and biochemical evidence of hyperandrogenism. Patients may be overwhelmed and confused by the variety of treatment options for AGA management, including over-the-count drugs with low evidence quality. Therefore, physicians must be aware of the current guidelines for the management of AGA based on evidence-based approaches to select better options for patients.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한의사협회-
dc.relation.isPartOfJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title안드로겐탈모증의 약물치료-
dc.title.alternativePharmacological therapeutics in androgenetic alopecia-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Dermatology (피부과학교실)-
dc.contributor.googleauthor김도영-
dc.contributor.googleauthor박수진-
dc.identifier.doi10.5124/jkma.2020.63.5.277-
dc.contributor.localIdA00384-
dc.relation.journalcodeJ01833-
dc.identifier.eissn2093-5951-
dc.subject.keywordAlopecia-
dc.subject.keywordDrug therapy-
dc.subject.keywordMinoxidil-
dc.subject.keywordFinasteride-
dc.subject.keywordDutasteride-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.citation.volume63-
dc.citation.number5-
dc.citation.startPage277-
dc.citation.endPage285-
dc.identifier.bibliographicCitationJOURNAL OF THE KOREAN MEDICAL ASSOCIATION, Vol.63(5) : 277-285, 2020-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.